STIM Stock Forecast: Neuronetics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Neuronetics, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 64 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Neuronetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
STIM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on STIM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | William Blair | Initiates | Outperform | — |
| 6 Nov 2026 | B. Riley Securities | Maintains | Buy | $5.00 → $6.00 |
| 17 Sept 2026 | BTIG | Reiterates | Buy | $6.00 |
| 11 Sept 2026 | B. Riley Securities | Initiates | Buy | $5.00 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | $6.00 |
| 11 Aug 2026 | BTIG | Maintains | Buy | $5.00 → $6.00 |
| 20 July 2026 | BTIG | Initiates | Buy | $5.00 |
| 19 Mar 2026 | Canaccord Genuity | Maintains | Buy | $7.00 → $3.00 |
| 6 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 14 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 12 Aug 2024 | William Blair | Downgrade | Market Perform | — |
| 14 May 2024 | William Blair | Upgrade | Outperform | — |
| 6 Mar 2024 | Piper Sandler | Reiterates | Overweight | — |
| 10 May 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 8 Mar 2023 | Canaccord Genuity | Maintains | Buy | — |
| 8 Mar 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 14 Oct 2021 | JMP Securities | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for STIM.
This page is one stock. Monday covers all of them.
STIM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
STIM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Neuronetics, Inc. returned −3.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
STIM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.8×
- Price / book
- 5.3×
- EV / EBITDA
- —
Cheaper than 71% of US stocks
Cheaper than 17% of US stocks
- Revenue growth (YoY)
- 12.5%
- Earnings growth (YoY)
- —
- Gross margin
- 51.1%
- Operating margin
- −9.1%
- Net margin
- —
Higher than 59% of US stocks
Higher than 63% of US stocks
Higher than 27% of US stocks
- Return on equity
- −85.6%
- Return on assets
- −6.6%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Neuronetics, Inc. has a market value of $123.5M and an enterprise value of $168.8M.
Revenue in the twelve months to 30 June 2026: $155.1M. The latest quarter grew 9.1% year on year.
Net income over the same four quarters: −$30.8M, a −19.9% net margin.
Diluted earnings per share, trailing twelve months: −$0.44.
Free cash flow in the twelve months to 30 June 2026: −$11.3M.
Neuronetics, Inc. employs 658 people — $236K of revenue per employee.
Data provided by Twelve Data
STIM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at STIM’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Neuronetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about STIM
What is the STIM stock price forecast for 2026-2027?
The median 12-month analyst price target for Neuronetics, Inc. is $6, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is STIM stock a buy right now?
Of the 5 analysts covering Neuronetics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neuronetics, Inc. 64 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank STIM?
As at 21 Nov 2026, Neuronetics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
Will STIM stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $6, and Ticker Nerd's factor model ranks Neuronetics, Inc. 64 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the STIM stock forecast for 2030?
No analyst covering Neuronetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.
How has STIM stock performed over the past year?
Neuronetics, Inc. returned -3.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Neuronetics, Inc. do?
Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments. Its core offering is the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation platform used primarily for adult patients with major depressive disorder.
About Neuronetics, Inc.
Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments. Its core offering is the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation platform used primarily for adult patients with major depressive disorder. The company also provides related treatment sessions and support services, serving psychiatric practices and mental health providers in the United States and international markets. Neuronetics operates at the intersection of medical devices and clinic services, combining device commercialization with patient care delivery. Its products are designed to expand access to non-drug therapeutic options for psychiatric and neurological conditions, making the company a significant participant in the neuromodulation market.
CEO Mr. Daniel L. Reuvers · 658 employees · United States · https://neurostar.com/neuronetics